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E-mail address: jun.ma@cchmc.org (J. Ma).Bicoid (Bcd) is a Drosophila morphogenetic protein and a transcriptional activator. Genetic studies
have suggested a role of sumoylation in Bcd function, but it is unknown how Bcd activity is affected
speciﬁcally by its own sumoylation status. Here we show that Bcd is sumoylated in Drosophila cells.
We identify a lysine residue of Bcd as the primary sumoylation site. Using a Bcd mutant defective in
being sumoylated, we show that sumoylation of Bcd is inhibitory to its ability to activate transcrip-
tion. We provide evidence suggesting that the SUMO moiety has an intrinsic inhibitory activity for
the activator function of Bcd.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Post-translational modiﬁcations play regulatory roles that im-
pact virtually every biological process. Understanding the molecu-
lar mechanisms of these regulatory roles is essential to our
knowledge about the basic operations and connectivity within cel-
lular and developmental systems. Conjugation of the small ubiqui-
tin-related modiﬁer (SUMO) to substrate proteins is a post-
translational modiﬁcation process referred to as sumoylation
[1,2]. Similar to ubiquitination, sumoylation also requires three
stepwise enzymatic reactions (E1, E2 and E3) [3,4]. This post-trans-
lational modiﬁcation has been suggested to play regulatory roles in
many molecular and cellular processes such as signal transduction,
transcription and intracellular trafﬁcking of proteins [5]. Because
of the wide spectrum of molecular and cellular activities impacted
by sumoylation, it is important to dissect the speciﬁcity of sumoy-
lation-mediated regulatory mechanisms.
Morphogens are molecules that form concentration gradients in
a developing tissue or embryo to induce distinct cell fates [6–10].
Bicoid (Bcd) is a morphogenetic protein that forms a concentration
gradient along the anterior–posterior (AP) axis in early Drosophila
embryos [11,12]. It is a homeodomain-containing transcriptionalchemical Societies. Published by E
Biomedical Informatics and
ch Foundation, 3333 Burnetactivator and controls AP patterning by activating its target genes
in a concentration-dependent manner [13–15]. One of its target
genes is hunchback (hb), which, in response to a concentration
threshold of the Bcd gradient, is expressed in the anterior half of
the embryo [16]. A Bcd-responsible hb enhancer element, which
is located upstream of the hb gene, contains multiple Bcd binding
sites [16]. This 250 bp enhancer element is sufﬁcient to confer
Bcd concentration-dependent responses to reporter genes in both
Drosophila embryos and cells [16,17]. Our recent studies have
shown that Bcd is subject to ubiquitination, a process that affects
the shape of the Bcd gradient [18]. Here we perform molecular
studies to investigate the regulatory role and speciﬁcity of another
post-translational modiﬁcation, namely, sumoylation.
Previous genetic studies have revealed a critical role of less-
wright (lwr), which encodes Ubc9 (the E2 conjugating enzyme in
sumoylation), in development. It was shown that mutations in
lwr (also known as semushi) cause a defect in the nuclear import
of Bcd and, consequently, a reduction in hb expression and AP pat-
terning defects [19]. These results suggest that Bcd is subject to
regulation by the sumoylation pathway during development. How-
ever, since lwr mutations disrupt globally this post-translational
process affecting many relevant substrates in the embryo, precisely
how the function of Bcd is regulated by its own sumoylation status
remains unclear. In this report, we show that the 489aa Bcd protein
is sumoylated in Drosophila cells. Among the three potential
sumoylation sites, we identify lysine at position 308 as a primary
sumoylation site for Bcd. Our analysis of Bcd-responsive reporterlsevier B.V. All rights reserved.
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to its function as a transcriptional activator. In addition, a single
SUMO moiety covalently attached to Bcd makes this protein al-
most completely non-functional as an activator. Our study thus
provides a ﬁrst molecular documentation of a speciﬁc regulatory
role of sumoylation on Bcd activity through the modiﬁcation of this
activator protein as a direct substrate.
2. Materials and methods
2.1. Plasmids and S2 cells
For expressing proteins in Drosophila S2 cells, the corresponding
cDNA sequences were cloned into the pAc5.1/V5-HisC vector
(Invitrogen). All plasmids used in this study were generated by
standard cloning methods and site-directed mutagenesis was per-
formed using a standard PCR-based method. Drosophila S2 cells
were cultured in the SFX insect medium (Hyclone) for all experi-
ments except for those involving dsRNAi treatment, where the
Schneider’s Drosophila medium (Invitrogen) containing 10% (v/v)
fetal bovine serum (Invitrogen) and 1 antibiotic–antimycotic
(Invitrogen) was used.
2.2. dsRNAi generation and treatment in Drosophila S2 cells
The protocols for dsRNAi generation and treatment in Drosophila
S2 cells were described previously [18]. PCR primers used for tar-
geting smt3 are 5’-TAA TAC GAC TCA CTA TAG GGA TGT CTG ACG
AAA AGA AGG G and 5’-TAA TAC GAC TCA CTA TAG GGT TAT GGA
GCG CCA CCA GTC TG. Two days after dsRNAi treatment, S2 cells
were transfected with a plasmid expressing HA-Bcd. After 40 h of
incubation, cells were then directly boiled in 1  SDS–PAGE (so-
dium dodecyl sulfate polyacrylamide gel electrophoresis) loading
buffer and subjected to Western blotting by the anti-HA antibody
(Convance) as described previously [18]. Loading control and the
efﬁciency of smt3 knockdown shown in Fig. 1B were detected by
anti-b-actin antibody (Abcam) and anti-Smt3 antibodies [20] (a
kind gift from Dr. Anne Dejean), respectively, in Western blotting.
2.3. In vivo sumoylation assay
To detect sumoylated Bcd products in S2 cells, plasmids
expressing both Bcd (wt or mutants) and SUMO proteins with suit-
able tags were co-transfected. 40 h after transfection, cells were
lysed in lysis buffer (50 mM Tris–HCl, pH7.5 and 1% SDS) for
10 min at 100 C. Cell extracts were then diluted by 1:10 in immu-
noprecipitation (IP) buffer (20 mM Tris–HCl, pH7.5, 150 mM NaCl,
10% glycerol, 0.1% NP-40, 1 mM DTT, complete protease inhibitor
cocktail (Roche)). Immunoprecipitation (IP) and Western blotting
were then performed as described previously [18].
2.4. DNA transfection and CAT reporter assay in Drosophila S2 cells
Transfection in S2 cells was carried out using the FuGENE HD
transfection reagent (Roche) according to the manufacturer’s
instructions. An optimal transfection mixture contained 2 lg DNA
and 6 ll FuGENE HD transfection reagent in 100 ll serum-free
medium. CAT reporter assays were carried out as described previ-
ously [17].
3. Results and discussion
3.1. A modiﬁed Bcd species in Drosophila cells suggests a role of
sumoylation
When wt Bcd was expressed in S2 cells (as an HA-Bcd fusion
protein), a minor band of 20 KDa larger than the full-length pro-tein was detected in Western blotting (Fig. 1A, lane 2). The size dif-
ference suggested that it may represent the product(s) of
posttranslational modiﬁcations by ubiquitin or ubiquitin-like mol-
ecules, such as SUMO. To investigate whether this minor band is a
ubiquitinated product of Bcd, we treated the cells with proteasome
inhibitors including MG132, lactacystin or epoxomicin. The
amount of the minor band relative to that of the full-length Bcd
protein was unaffected by these treatments (data not shown);
nor was it affected by the overexpression of ubiquitin in cells (data
not shown). These results suggest that, although Bcd is subject to
ubiquitination in S2 cells [18], this minor band of Bcd is not a ubiq-
uitinated product.
To investigate whether this minor band of Bcd is a sumoylated
product, we treated S2 cells with dsRNAi against smt3, the Dro-
sophila gene encoding SUMO. The efﬁciency of dsRNAi knockdown
was conﬁrmed by a reduction of the amount of SUMO protein in
treated cells (Fig. 1B, lane 2). Fig. 1C shows that such a treatment
dramatically reduced the relative amount of this minor band of
Bcd (lane 2), suggesting it may represent a sumoylated product.
Similar to ubiquitination, sumoylation is also a reversible process,
and the Smt3-deconjugating enzyme Ulp1 can catalyze the reverse
reaction [21]. We reasoned that, if this minor protein species is in-
deed a sumoylated product of Bcd, it should exhibit sensitivity to
Ulp1 levels in S2 cells. Our results (Fig. 1D) show that Ulp1 overex-
pression in S2 cells almost completely abolished this minor band
(lane 2). Together, these results suggest a role of sumoylation in
the formation of the minor band of Bcd present in S2 cells.
3.2. Bcd is sumoylated in Drosophila cells
To directly visualize the sumoylated products of Bcd, we co-
transfected S2 cells with plasmids expressing HA-Bcd and FLAG-
SUMO. Here we used the anti-FLAG antibody to pull down the
sumoylated products in cell extracts and detected Bcd by the
anti-HA antibody in Western blotting. Sumoylated Bcd species
were detected in the pull-down products when, and only when,
both plasmids were co-transfected into the cells (Fig. 1E, lane 6;
see other lanes for controls). In a reciprocal setting, we co-transfec-
ted S2 cells with plasmids expressing FLAG-Bcd and HA-SUMO. We
used anti-FLAG to pull down Bcd and detected the sumoylated spe-
cies by the anti-HA antibody in Western blotting. Similar results
were obtained in these reciprocal experiments (Fig. 1F, lane 6,
see other lanes for controls). In both experiments, we detected
not only a Bcd product with a molecular weight shift indicative
of mono-sumolylation, but also protein species indicative of
poly-sumoylation with progressively decreasing amounts. To-
gether, these results show that Bcd is sumoylated in Drosophila
S2 cells.
3.3. Identiﬁcation of K308 as the primary sumoylation site for Bcd
SUMO is generally conjugated to a lysine residue within a con-
sensus motif, wKxE/D (where w is a large hydrophobic residue and
x is any residue) [4]. An analysis of the primary sequence of Bcd re-
veals three potential sumoylation motifs with lysine residues at
positions 79, 308 and 355. To determine the possible roles of these
lysine residues in Bcd sumoylation, we mutated them to alanines
either individually or combinatorially through site-directed muta-
genesis. We performed assays in S2 cells to determine the sumol-
yation status of these mutants. As shown in Fig. 2, sumoylated Bcd
products became almost undetectable in cells expressing the Bcd
mutant with K308 mutated to A (referred to as BcdK308A, lane 11).
A double mutation that has both K308A and K355A alterations, also
had a similar effect in preventing the formation of the sumoylated
Bcd products (lane 10). In contrast, individually mutating the other
two lysine residues (K79 or K355) to alanines had no detectable ef-
Fig. 1. Bcd is sumoylated in Drosophila S2 cells. (A) A Western blotting (WB) detecting a minor protein species of HA-Bcd in S2 cells. Transfected cells were directly boiled in
1 SDS–PAGE loading buffer and subject to SDS–PAGE and Western blotting using an antibody against HA. HA-Bcd and the minor protein bands are marked (*for the minor
band). The molecular weight standards are shown on the right. (B) The amount of SUMO protein is reduced by smt3 dsRNAi. The loading control is represented by b-actin. (C
and D) The amount of the minor protein (relative to the full-length Bcd) is reduced by smt3 dsRNAi (C) or overexpression of Ulp1 (D). (E) S2 cells were co-transfected with
plasmids expressing FLAG-tagged SUMO and HA-tagged Bcd. Cell extracts were subject to immunoprecipitation (IP) using the anti-FLAG antibody and Western blotting using
the anti-HA antibody. Sumoylated Bcd species are marked. A ladder of sumoylated Bcd bands was detected (with the lowest molecular weight (MW) band corresponding to
the minor band shown in A and having the highest intensity), suggesting that, similar to ubiquitination, Bcd may be subject to poly-sumoylation. (F) Same as panel E, except
under a reciprocal experimental setting where Bcd is FLAG-tagged and SUMO is HA-tagged.
Fig. 2. Identiﬁcation of K308 as the primary sumoylation site for Bcd. Experimental
procedures are described in Fig. 1E. Here, both wt Bcd (w; lane 8) and Bcd mutants
(lanes 9–12) were tested, with the mutants having the following alterations: K79A
(m1; lane 9), K308A and K355A (m2; lane 10), K308A (m3; lane 11) or K355A (m4; lane
12). Results from a control experiment with the expression vector alone (-) are
shown in lane 7. The non-sumoylated and sumoylated Bcd protein species are
marked, with molecular weight standards shown on the left. The detected heavy
chain of IgG is marked with *. Input lanes 1–6 show Western blotting results from
cell extracts prior to IP.
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the lysine residue at position 308 is the primary sumoylation site
for Bcd.3.4. Bcd activity is subject to inhibition by sumoylation
Sumoylation has been implicated to have important regulatory
roles in modulating the function of transcriptional activators
[22,23]. To determine speciﬁcally whether the function of Bcd as
an activator is subject to regulation by the sumoylation status of
itself, we performed reporter assays in S2 cells. Here we used a
Bcd-responsive reporter gene expressing chloramphenicol acetyl-
transferase (CAT). The expression of this reporter, hb-CAT, is con-
trolled by the 250 bp hb enhancer element [17]. We co-
transfected cells with effector plasmids expressing either the wt
or mutant forms of Bcd. Fig. 3A shows that both wt Bcd and
BcdK308A activated the hb-CAT reporter in a dose-dependent man-
ner. However, BcdK308A achieved higher levels of reporter activity
than wt Bcd at all concentrations tested. The difference between
the plateau levels of the reporter activity is >2-fold
(p = 4.5  103 at 150 ng effecter plasmids, n = 3). The activity dif-
ference between BcdK308A and wt Bcd is not due to differences in
their accumulated protein levels in cells (Fig. 3B). These results
suggest that sumoylation of Bcd is inhibitory to its ability to acti-
vate transcription, and removing the primary sumoylation site of
Bcd renders the mutant protein insensitive to this inhibitory
mechanism.
3.5. The SUMO moiety covalently linked to Bcd is sufﬁcient to inhibit
its activity
To directly and speciﬁcally document the inhibitory role of
SUMO on Bcd activity, we covalently linked SUMO to the C termi-
Fig. 3. Sumoylation of Bcd negatively affects its activator function in Drosophila S2 cells. (A) The BcdK308A mutant activates reporter expression to higher levels in S2 cells. A
hb-CAT reporter was co-transfected into S2 cells with increasing amounts of effector plasmids expressing either HA-tagged wt Bcd or BcdK308A (shown as mut, which
corresponds to m3 in Fig. 2.). CAT activities shown are relative to those obtained from cells transfected with 100 ng effector plasmid expressing wt Bcd (set to 100). Error bars
show standard deviations from three independent experiments. (B) Western blotting results showing comparable levels of wt Bcd and BcdK308A mutant. Loading volume was
adjusted by transfection efﬁciency determined by b-galactosidase activities expressed from a lacZ control plasmid. (C) CAT reporter assays comparing the activities of HA-
tagged wt Bcd and a fusion protein Bcd-SUMO. The mean and standard deviation of relative CAT activities (from three independent experiments) are: 85.79 ± 9.45 and
0.22 ± 0.06 for wt Bcd and Bcd-SUMO, respectively. To speciﬁcally evaluate the activation function of Bcd-SUMO, the CAT assays were performed under conditions where
similar protein levels were expressed for Bcd and Bcd-SUMO (see panel D). (D) A Western blotting showing HA-tagged Bcd and Bcd-SUMO levels in the same cells used for
CAT reporter assays in C. The effector plasmid was: 50 ng and 300 ng for Bcd and Bcd-SUMO, respectively, to achieve comparable protein levels in cells. The loading amount
for each lane was adjusted by b-galactosidase activities expressed from a lacZ control plasmid.
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self from becoming conjugated to other proteins (as sumoylation
substrates), we mutated the GG residues (which are needed for
its conjugation with protein substrates [24]) at the C terminus of
SUMO to AA. Compared with wt Bcd, this fusion protein, referred
to as Bcd-SUMO, almost completely lost its ability to activate hb-
CAT (Fig. 3C) when the two proteins were expressed at comparable
levels in cells (Fig. 3D). Together, these results suggest that the
SUMO moiety has an intrinsic inhibitory activity for the activator
function of Bcd.
4. Concluding remarks
Our experiments document that Bcd is a substrate of sumoyla-
tion in S2 cells. The use of a speciﬁc Bcd mutant that has a single
amino acid change and is defective of being sumoylated shows that
the function of Bcd as an activator is subject to inhibition by its
own sumoylation status. A single SUMO moiety covalently linked
to Bcd is sufﬁcient to confer such an inhibitory effect, suggesting
an intrinsic inhibitory activity of this moiety for the activator func-
tion of Bcd. Our reporter assay results (Fig. 3A and B) show the Bcd
level in cells where half maximal reporter activities were detected
was not signiﬁcantly different between wt and mutant proteins,
suggesting that sumoylation primarily inhibits the activation func-
tion of Bcd. A recent study has shown that Bcd is also subject to
sumoylation in early Drosophila embryos [25]. The BcdK308A mu-
tant generated in this study has enabled us to investigate how
the activity of Bcd, a direct and speciﬁc substrate of sumoylation,
is regulated by this post-translational modiﬁcation during devel-
opment. As detailed elsewhere [26], our results show that thisBcd mutant also has an increased ability (of a comparable magni-
tude) to activate hb transcription in embryos. Unlike cultured cells,
cells (nuclei) in the early Drosophila embryo undergo synchronous
mitotic divisions, allowing us to follow Bcd activity as a function of
time. Our studies in embryos suggest a role of Bcd sumoylation in
modulating the length of the action time of Bcd during a mitotic
interphase in early embryos.
Our results described here identify a speciﬁc regulatory role of
sumoylation on the activator function of Bcd. They suggest that,
although an impaired sumoylation pathway (caused by lwr muta-
tions in embryos) has been shown to affect the nuclear import of
Bcd [19], the primary regulatory role of sumoylation on Bcd as a di-
rect substrate is the inhibition of its ability to activate transcrip-
tion. As shown by both our own studies in embryos [26] and
those in [27], a Bcd mutant lacking its primary sumoylation site
forms a normal gradient and remains localized to the nucleus.
Thus, the nuclear import defect of Bcd in lwrmutant embryos must
be reﬂective of the dependence of other molecules, such as those in
the nuclear import machinery [19], on sumoylation as substrates.
Our studies thus illustrate the importance of delineating the spec-
iﬁcity of the regulatory roles of post-translational modiﬁcations
such as sumoylation.
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